Cargando…

Glutaminyl cyclase-mediated toxicity of pyroglutamate-beta amyloid induces striatal neurodegeneration

BACKGROUND: Posttranslational modifications of beta amyloid (Aβ) have been shown to affect its biophysical and neurophysiological properties. One of these modifications is N-terminal pyroglutamate (pE) formation. Enzymatic glutaminyl cyclase (QC) activity catalyzes cyclization of truncated Aβ(3-x),...

Descripción completa

Detalles Bibliográficos
Autores principales:	Becker, Andreas, Kohlmann, Stephanie, Alexandru, Anca, Jagla, Wolfgang, Canneva, Fabio, Bäuscher, Christoph, Cynis, Holger, Sedlmeier, Reinhard, Graubner, Sigrid, Schilling, Stephan, Demuth, Hans-Ulrich, von Hörsten, Stephan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850634/ https://www.ncbi.nlm.nih.gov/pubmed/24083638 http://dx.doi.org/10.1186/1471-2202-14-108

Ejemplares similares

Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms
por: Hartlage-Rübsamen, Maike, et al.
Publicado: (2011)

The isoenzyme of glutaminyl cyclase is an important regulator of monocyte infiltration under inflammatory conditions
por: Cynis, Holger, et al.
Publicado: (2011)

Identification of Glutaminyl Cyclase Genes Involved in Pyroglutamate Modification of Fungal Lignocellulolytic Enzymes
por: Wu, Vincent W., et al.
Publicado: (2017)

Intraneuronal pyroglutamate-Abeta 3–42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model
por: Wirths, Oliver, et al.
Publicado: (2009)

A glutaminyl cyclase-catalyzed α-synuclein modification identified in human synucleinopathies
por: Hartlage-Rübsamen, Maike, et al.
Publicado: (2021)

Linked Production of Pyroglutamate-Modified Proteins via Self-Cleavage of Fusion Tags with TEV Protease and Autonomous N-Terminal Cyclization with Glutaminyl Cyclase In Vivo
por: Shih, Yan-Ping, et al.
Publicado: (2014)

Soluble Variants of Human Recombinant Glutaminyl Cyclase
por: Castaldo, Cristiana, et al.
Publicado: (2013)

In vitro and in silico determination of glutaminyl cyclase inhibitors
por: Tran, Phuong-Thao, et al.
Publicado: (2019)

Mammalian-like type II glutaminyl cyclases in Porphyromonas gingivalis and other oral pathogenic bacteria as targets for treatment of periodontitis
por: Taudte, Nadine, et al.
Publicado: (2021)

Distinct glutaminyl cyclase expression in Edinger–Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Aβ pathology in Alzheimer’s disease
por: Morawski, Markus, et al.
Publicado: (2010)

Natural Products from Microalgae with Potential against Alzheimer’s Disease: Sulfolipids Are Potent Glutaminyl Cyclase Inhibitors
por: Hielscher-Michael, Stephanie, et al.
Publicado: (2016)

N-terminal pyroglutamate formation in CX3CL1 is essential for its full biologic activity
por: Kehlen, Astrid, et al.
Publicado: (2017)

Prion-Like Behavior and Tau-dependent Cytotoxicity of Pyroglutamylated β-Amyloid
por: Nussbaum, Justin M., et al.
Publicado: (2012)

Upregulation of Glutaminyl Cyclase Contributes to ERS-Induced Apoptosis in PC12 Cells
por: Shang, Qi, et al.
Publicado: (2022)

The Bacteroidetes Q-rule and glutaminyl cyclase activity increase the stability of extracytoplasmic proteins
por: Szczęśniak, Katarzyna, et al.
Publicado: (2023)

Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges
por: Cynis, Holger, et al.
Publicado: (2016)

Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-Abeta Formation
por: Hartlage-Rübsamen, Maike, et al.
Publicado: (2018)

Tetrahydroimidazo[4,5-c]pyridine-Based Inhibitors of Porphyromonas gingivalis Glutaminyl Cyclase
por: Ramsbeck, Daniel, et al.
Publicado: (2021)

Malaria parasite evades mosquito immunity by glutaminyl cyclase–mediated posttranslational protein modification
por: Kolli, Surendra Kumar, et al.
Publicado: (2022)

Isoglutaminyl cyclase contributes to CCL2-driven neuroinflammation in Alzheimer’s disease
por: Hartlage-Rübsamen, Maike, et al.
Publicado: (2015)

Human glutaminyl cyclase and bacterial zinc aminopeptidase share a common fold and active site
por: Booth, Rachell E, et al.
Publicado: (2004)

Microarray evidence of glutaminyl cyclase gene expression in melanoma: implications for tumor antigen specific immunotherapy
por: Gillis, John Stuart
Publicado: (2006)

Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and target for cancer immunotherapy
por: Logtenberg, Meike E. W., et al.
Publicado: (2019)

Repurposing FDA‐Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease
por: Xu, Chenshu, et al.
Publicado: (2020)

Passive Immunization against Pyroglutamate-3 Amyloid-β Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study
por: Frost, Jeffrey L., et al.
Publicado: (2012)

Combination of the Glutaminyl Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain Aβ Pathology in Transgenic Mice
por: Hoffmann, Torsten, et al.
Publicado: (2021)

A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects
por: Lues, Inge, et al.
Publicado: (2015)

Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer’s disease patients
por: Bridel, Claire, et al.
Publicado: (2017)

Development and evolution of human glutaminyl cyclase inhibitors (QCIs): an alternative promising approach for disease-modifying treatment of Alzheimer's disease
por: Chen, Daoyuan, et al.
Publicado: (2023)

Disturbed Ca(2+) Homeostasis Increases Glutaminyl Cyclase Expression; Connecting Two Early Pathogenic Events in Alzheimer’s Disease In Vitro
por: De Kimpe, Line, et al.
Publicado: (2012)

Chronic treatment with the (iso-)glutaminyl cyclase inhibitor PQ529 is a novel and effective approach for glomerulonephritis in chronic kidney disease
por: Kanemitsu, Naotoshi, et al.
Publicado: (2021)

Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactions
por: Baumann, Niklas, et al.
Publicado: (2021)

Structural Analysis and Aggregation Propensity of Pyroglutamate Aβ(3-40) in Aqueous Trifluoroethanol
por: Dammers, Christina, et al.
Publicado: (2015)

Metabolic Acidosis Due To Pyroglutamic Acid
por: Serpa, Maria João, et al.
Publicado: (2018)

Flucloxacillin and paracetamol induced pyroglutamic acidosis
por: Zand Irani, Anis, et al.
Publicado: (2021)

Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study
por: Scheltens, Philip, et al.
Publicado: (2018)

Purification and Characterization of Recombinant N-Terminally Pyroglutamate-Modified Amyloid-β Variants and Structural Analysis by Solution NMR Spectroscopy
por: Dammers, Christina, et al.
Publicado: (2015)

Comprehensive Characterization of the Pyroglutamate Amyloid-β Induced Motor Neurodegenerative Phenotype of TBA2.1 Mice
por: Dunkelmann, Tina, et al.
Publicado: (2018)

Proteostasis in striatal cells and selective neurodegeneration in Huntington’s disease
por: Margulis, Julia, et al.
Publicado: (2014)

4,4′-Bipyridine–pyroglutamic acid (1/2)
por: Arman, Hadi D., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_id0c1i6nf4ukm3crl7tbrlp5m3